Does diphenhydramine cause QTc prolongation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Diphenhydramine Can Cause QTc Prolongation, Particularly in Overdose Settings

Yes, diphenhydramine causes QTc prolongation and is associated with increased risk of severe QT prolongation, especially in overdose situations or when combined with other risk factors.

Evidence Base

The most recent and highest quality evidence comes from a 2020 prospective multicenter study of over 6,000 acute drug overdose patients, which identified diphenhydramine as a significant independent predictor of severe QTc prolongation (QTc ≥500 ms) using multivariable analysis 1. This study specifically categorized diphenhydramine among sodium channel blockers associated with increased adjusted odds of severe QTc prolongation following acute overdose.

A 2022 poison center study further confirmed that diphenhydramine had a statistically significant association with QTc >500 ms, even though it is not listed in CredibleMeds' "Known Risk of TdP" category 2. This study analyzed 760 exposures and found QTc ≥500 ms in 18.2% of cases overall, with diphenhydramine showing significant correlation with prolongation.

Clinical Context and Risk Stratification

When QTc Prolongation Occurs:

  • Overdose situations are the primary concern 3, 4, 1
  • Therapeutic doses listed in FDA labeling 5 do not specifically warn about QTc prolongation, suggesting lower risk at standard dosing
  • Risk increases with multiple QT-prolonging factors present simultaneously 6

Critical Risk Factors to Assess:

According to the 2023 Canadian Cardiovascular Society guidelines 6:

  • Female sex (well-established higher risk)
  • Electrolyte disturbances (hypokalemia, hypomagnesemia)
  • Concurrent QT-prolonging medications
  • Underlying cardiac disease
  • Renal dysfunction (affects drug clearance)
  • Elderly patients
  • Baseline QTc >470 ms (women) or >450 ms (men)

Clinical Approach

When to Monitor ECG:

You should obtain an ECG if:

  • Patient presents with diphenhydramine overdose 3, 1
  • Combining diphenhydramine with other QT-prolonging drugs 6
  • Patient has ≥2 risk factors for QT prolongation 6
  • History of cardiac abnormalities or prior QTc prolongation 3

Routine ECG monitoring is NOT needed for:

  • Otherwise healthy patients on therapeutic doses
  • Absence of other risk factors 6

Danger Thresholds:

The 2023 guidelines clearly state that increased risk for Torsades de Pointes occurs when 6:

  • QTc exceeds 500 ms, OR
  • Drug increases QTc by >60-70 ms, particularly when this develops rapidly

Management in Overdose:

Based on case reports 3, 4:

  • Admit patients with diphenhydramine overdose who have QTc prolongation and cardiac risk factors
  • Monitor continuously for ventricular arrhythmias
  • Life-threatening dysrhythmias (VT/VF, Torsades) are rare but documented 2
  • Correct electrolyte abnormalities immediately
  • Consider cardiology consultation for QTc >500 ms

Important Caveats

The Terfenadine Precedent:

The 2010 AHA/ACC statement 7 provides historical context: the antihistamine terfenadine had nearly 100 million prescriptions written before its very small TdP risk was recognized. The overall incidence was exceedingly small and largely confined to patients with specific risk factors. This suggests that first-generation antihistamines like diphenhydramine likely carry low absolute risk at therapeutic doses in patients without risk factors.

Sodium Channel Blocking Effects:

Diphenhydramine's classification as a sodium channel blocker 1 means it can cause QRS prolongation in addition to QTc prolongation, particularly in overdose. This distinguishes it from pure IKr (potassium channel) blockers and may contribute to its arrhythmogenic potential through multiple mechanisms.

Not on High-Risk Lists:

Despite evidence of QTc prolongation, diphenhydramine is not categorized in CredibleMeds' "Known Risk of TdP" list 2, suggesting regulatory bodies view the absolute risk as lower than drugs like methadone, haloperidol, or Class III antiarrhythmics that have 1-10% TdP incidence 7.

Practical Recommendations

Before prescribing diphenhydramine, check 6:

  • www.crediblemeds.org for drug interactions
  • Current medication list for other QT-prolonging drugs
  • Recent electrolytes if patient on diuretics or has renal disease
  • Baseline ECG only if ≥2 risk factors present

Consider safer alternatives when:

  • Patient already on QT-prolonging medication
  • Multiple cardiac risk factors present
  • History of arrhythmias or syncope

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.